Huntington National Bank’s Janux Therapeutics JANX Stock Holding History

Huntington National Bank’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14	Hold	1	–	–	﹤0.01%	3638
2025 Q4	$14	Hold	1	–	–	﹤0.01%	3551
2025 Q3	$24	Sell	1 -57	-98%	-$1.39K	﹤0.01%	3339
2025 Q2	$1.34K	Buy	58 +15	+35%	+$395	﹤0.01%	2291
2025 Q1	$1.16K	Buy	43 +19	+79%	+$716	﹤0.01%	2339
2024 Q4	$1.28K	Sell	24 -17	-41%	-$899	﹤0.01%	2343
2024 Q3	$1.86K	Buy	41 +20	+95%	+$870	﹤0.01%	2252
2024 Q2	$880	Sell	21 -8	-28%	-$376	﹤0.01%	2324
2024 Q1	$1.09K	Buy	29 +28	+2,800%	+$610	﹤0.01%	2266
2023 Q4	$11	Buy	+1	New	+$9	﹤0.01%	3415

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Huntington National Bank's JANX Position: Q1 2026 in Review

Huntington National Bank held its Janux Therapeutics (JANX) position steady in Q1 2026 at 1 share worth $14. The position accounts for ﹤0.01% of the portfolio, ranked #3638.

Huntington National Bank first reported a position in JANX in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.86K in Q3 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

Huntington National Bank held 1 share of Janux Therapeutics worth $14 as of Q1 2026.
Huntington National Bank left its Janux Therapeutics share count unchanged in Q1 2026.
Janux Therapeutics made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #3638 holding.
Huntington National Bank first reported a position in Janux Therapeutics in Q4 2023 and has held it in 10 quarters since.
Huntington National Bank's Janux Therapeutics position peaked at $1.86K in Q3 2024.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.